Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Adrenoleukodystrophy - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Adrenoleukodystrophy - Pipeline Insight, 2024" report provides comprehensive insights about 10+ companies and 11+ pipeline drugs in Adrenoleukodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adrenoleukodystrophy pipeline landscape is provided which includes the disease overview and Adrenoleukodystrophy treatment guidelines. The assessment part of the report embraces, in depth Adrenoleukodystrophy commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adrenoleukodystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Adrenoleukodystrophy R&D. The therapies under development are focused on novel approaches to treat/improve Adrenoleukodystrophy.
Adrenoleukodystrophy Emerging Drugs Chapters
This segment of the Adrenoleukodystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adrenoleukodystrophy Emerging Drugs
Leriglitazone: Minoryx Therapeutics
Minoryx's lead program is a selective, differentiated PPAR gamma agonist (leriglitazone) under development for the treatment of X-linked Adrenoleukodystrophy (X-ALD); it has the potential to treat both the severe cerebral form of ALD (cALD) and the chronic form, adrenomyeloneuropathy (AMN), as well as other orphan CNS diseases, such as Friedreich's Ataxia (FRDA) and Rett's disease. The drug is currently under preregistration stage of development for the treatment of patients with Adrenoleukodystrophy.
VK0214: Viking Therapeutics
Viking is developing VK0214, which is a novel, orally available small molecule thyroid hormone receptor agonist that possesses selectivity for the beta receptor subtype. VK0214 has been granted orphan drug designation by the US FDA for the treatment of X-ALD. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Adrenoleukodystrophy.
Adrenoleukodystrophy: Therapeutic Assessment
This segment of the report provides insights about the different Adrenoleukodystrophy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Adrenoleukodystrophy
There are approx. 10+ key companies which are developing the therapies for Adrenoleukodystrophy. The companies which have their Adrenoleukodystrophy drug candidates in the most advanced stage, i.e. Preregistration include, Minoryx Therapeutics.
Adrenoleukodystrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adrenoleukodystrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adrenoleukodystrophy drugs.
Key Questions
- How many companies are developing Adrenoleukodystrophy drugs?
- How many Adrenoleukodystrophy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adrenoleukodystrophy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Adrenoleukodystrophy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Adrenoleukodystrophy and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Minoryx Therapeutics
- Viking Therapeutics
- Poxel
- MedDay Pharmaceuticals
- SwanBio Therapeutics
Key Products
- Leriglitazone
- VK0214
- PXL-770
- MD1003
- SBT101
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Adrenoleukodystrophy Report Insights
- Adrenoleukodystrophy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Adrenoleukodystrophy Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/bs5den
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
